Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Non-Deal Roadshow (July 2026)
17 slides from Island Pharmaceuticals's roadshow presentation, Jul 27, 2026
Slide 1: Techknow Invest Roadshow presentation
27 July 2026 ASX Announcement Techknow Invest Roadshow presentation MELBOURNE Australia, 27 July 2026: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) advises that non- executive chairman, Mr Jason Carroll will present at the TechKnow Inves
Slide 2: Go paperless with the share registry
Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company’s website. Visit www.islandpharmaceuticals.com for more on Island. Island Ph
Slide 3: Mr. Jason Carroll - Non-Executive Chairman, Dr. David Foster
‘ Mr. Jason Carroll - Non-Executive Chairman - Dr. David F July 2026
Slide 4: Important Information
Important Information This cisclsimer applies to tis resentation and the information contained init Presentation). By reading this disclaimer you a ee tobe bound by it.The Presentation has been prepared by island Pharmaceuticas Limited and all elated bodies corporate (Company) Confidential informati
Slide 5: Island Pharmaceuticals: two programs targeting infectious diseases
ISLAND PHARM S (ASX: ILA) TWO,PROGRAMS TARGETING INFECTIOUS DISEASES _ 5) Phase 2a/b PROTECT clinical trial in dengue go Two, well advanced clinical stage programs & complete 74 Positive FDA feedback on Animal Rule («) Major market potential via both programs regulatory path |" Multiple near term cl
Slide 6: Company Overview
Company Overview Shares on issue": Price per share’: Cash at bank (31 Ma Potential additi where curre e & volume (12 mont Island Pharmaceuticals Limited 295,916,682 $118.6m nei Pots ae 1 Substantial shareholders Dr William James Garner$ 15.50% Jason Alan Carroll® 11.92% MWP Partners Limited* 8.25% D
Slide 7: Ebola & Marburg Viral Threats
Ebola & Marburg Viral Threats An urgent and growing global security challenge Limited countermeasures: No approved therapeutics or vaccines for Marburg or Bundibugyo global capacity There are no flovirus therapeutics capable of cross-strain protection BSL-4 pathogens: Require maximum containment; li
Slide 8: Galidesivir designed as a biodefence countermeasure
Galidesivir is designed as a Biodefence c protect and defend the backbone of US + Estimated Tier Pome Notes HIGH-PRIORITY RECIPIENTS FOR GUARANTEED TREATMENT COURSE President + Cabinet ~25 Includes POTUS, VP, Cabinet Secretaries Congressional oa Speaker, Majority/Minority Leaders, * President + Cabi
Slide 9: Dual Development Strategy
Dual Development Strategy Two complementary pathways advancing Galidesivir towards re Pathway 1 Pathway 2 FDA Animal Rule Program Human Ebola Study USAMRIID Marburg challenge study WHO MEURI Framework Controlled non-human primate efficacy data Real-world clinical data Marburg virus model Bundibugyo
Slide 10: Animal Rule disrupts the established R&D pathway
Animal Rule disrupts the established R In vivo ‘N Experiment experiments Phase 1 Phase 2 Phase 3 a ma ‘ oe F : F AG ’ NDA » in vitro (animal clinical trials . clinical trials » clinical trials y studies) pay a aes Drug Experiment ee t: PORTE! I Exp experiments — oFficac design in vitro (2 animal Sun
Slide 11: Government-Approved Africa Protocol
Government-Approved Africa Protocol Monitored Emergency Use of Unregistered and Investigational Government approvals have been secured to evaluate Galidesivir during the active Bundibugyo Ebola outbreak in Uganda under the WHO MEURI framework, creating a unique opportunity to generate prospective hu
Slide 12: Regulatory & Commercial Opportunity
Regulatory & Commercial Opportunity Aclear pathway to regulatory approval and commercialisation Regulatory pathway forGalidesivi > FDA Animal Rule supported by pivotal Marburg efficacy studies. >» WHO MEURI framework felceyureliare) prospective human data in Ebola or other outbreaks. Island Pharmace
Slide 13: Marburg NHP Survival
MARBURG NHP SURVIVAL 94% survival in Marburg NHP Model with treatment in ifs post-infection 100 eS . 8 $ Sd = 6/6 animals survived when dosed 48 hours 2 post infection 3 - = @ TxXihpl = 6/6 animals survived when dosed 24 hours Da post infection 8 40 @ TX24hPl € a P A 5/6 animals survived when dosed
Slide 14: Ebola NHP Survival
EBOLA NHP SURVIVAL Robust efficacy in Ebola NHP model with delayed dosing Survival of rhesus non-human primates challenged with Ebola virus following intramuscular administration of 100 mg/kg BID loading dose followed by 25 mg/kg BID for 10 days. 100 \ _ 1 g 80 H — 100% survival when treatment comme
Slide 15: A Proven Path for Bioterror Threat Countermeasures
A PROVEN PATH FOR BIOTERROR THREAT CO Year SNS Sales contract Undor Sis eean) Gaeot Approved Peo) (usb) Term Contract Emergent BioSolutions | raxibacumab 2012 Inhalational Anthrax $450M Syrs Yes [Anaphylaxis No kaléo AUVEQ 202 (emergency ~$100M+ Expired (contract countermeasure) expired) 7 Biothrax/
Slide 16: Near-Term Catalysts
Near-Term Catalysts A.number.of value catalysts pending in the coming months Mileston: ame Establish Fellows Program to provide expert access to strategic subject matter KOLs Complete FDA feedback on Galidesivir protocol clarifying questions Received Government-approved deployment of Galidesivir und
Slide 17: Island Pharmaceuticals contact and social links
islandpharmace @lslandPharma fa Island Pharmaceuticals
Island Pharmaceuticals — Non-Deal Roadshow (July 2026) on 6ix